Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bacterial Pneumonia Responds Best to an Antibiotic and Steroid Cocktail

By LabMedica International staff writers
Posted on 21 Oct 2008
Researchers working with a mouse model of bacterial pneumonia have found that treatment with a combination of antibiotic and corticosteroid was more effective than antibiotic treatment alone in curing the disease.

Mycoplasma pneumoniae causes a relatively benign type of respiratory disease that accounts for 20 to 30% of all community-acquired pneumonia cases. More...
Traditionally, infections with M. pneumoniae are treated with antibiotics. However, while this treatment eliminates the causative agent of the respiratory disease, it does not aid in reducing inflammation and swelling in the lungs.

In a study published in the October 15, 2008, issue of the Journal of Infectious Diseases, investigators at the University of Texas Southwestern Medical Center (Dallas, USA) combined traditional antibiotic treatment (in this study clarithromycin) to kill the pathogenic bacteria with corticosteroid treatment to reduce inflammation.

Corticosteroids are a class of steroid hormones that are produced in the adrenal cortex. They are involved in a wide range of physiologic systems such as stress response, immune response and regulation of inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte levels, and behavior. The steroid used in this study was dexamethasone.

Mice were infected with M. pneumoniae and then separated into separate treatment groups. Different groups were treated with clarithromycin, dexamethasone, combined clarithromycin/dexamethasone, or a placebo daily. The mice were evaluated at the start of the therapy and after one, three, and six days of treatment.

Results showed that while antibiotic therapy with clarithromycin had the greatest effect on reducing concentrations of M. pneumoniae, combination antibiotic/steroid therapy had the greatest effect on decreasing levels of cytokines and chemokines as well as reducing lung inflammation.

"It turns out that the group that got both the antibiotic and the steroids did the best,” said senior author Dr. Robert Hardy, associate professor of internal medicine and pediatrics at the University of Texas Southwestern Medical Center. "The inflammation in their lungs got significantly better. Some people might think that if you give steroids, it would counteract the effect of the antibiotic, but it turns out you need the antibiotic to kill the bug and the steroid to make the inflammation in the lung from the infection get better. The steroids do not kill the bugs, but they do help restore health.”

Related Links:
University of Texas Southwestern Medical Center



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.